Lantern Net Income Applicable To Common Shares from 2010 to 2024

LTRN Stock  USD 6.16  0.65  9.54%   
Lantern Pharma Net Loss yearly trend continues to be very stable with very little volatility. Net Loss is likely to grow to about -12.2 M this year. Net Loss is the net income that remains after preferred dividends have been deducted, available to common shareholders. View All Fundamentals
 
Net Loss  
First Reported
2010-12-31
Previous Quarter
-12.8 M
Current Value
-12.2 M
Quarterly Volatility
M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Lantern Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lantern main balance sheet or income statement drivers, such as Depreciation And Amortization of 183.6 K, Interest Expense of 246.8 K or Selling General Administrative of 5.7 K, as well as many exotic indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.19. Lantern financial statements analysis is a perfect complement when working with Lantern Pharma Valuation or Volatility modules.
  
This module can also supplement Lantern Pharma's financial leverage analysis and stock options assessment as well as various Lantern Pharma Technical models . Check out the analysis of Lantern Pharma Correlation against competitors.
To learn how to invest in Lantern Stock, please use our How to Invest in Lantern Pharma guide.

Latest Lantern Pharma's Net Income Applicable To Common Shares Growth Pattern

Below is the plot of the Net Income Applicable To Common Shares of Lantern Pharma over the last few years. It is the net income that remains after preferred dividends have been deducted, available to common shareholders. Lantern Pharma's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lantern Pharma's overall financial position and show how it may be relating to other accounts over time.
Net Income Applicable To Common Shares10 Years Trend
Slightly volatile
   Net Income Applicable To Common Shares   
       Timeline  

Lantern Net Income Applicable To Common Shares Regression Statistics

Arithmetic Mean(5,034,887)
Coefficient Of Variation(100.29)
Mean Deviation4,317,725
Median(1,726,417)
Standard Deviation5,049,243
Sample Variance25.5T
Range12.5M
R-Value(0.82)
Mean Square Error9T
R-Squared0.67
Significance0.0002
Slope(925,246)
Total Sum of Squares356.9T

Lantern Net Income Applicable To Common Shares History

2024-12.2 M
2023-12.8 M
2022-14.3 M
2021-12.4 M
2020-5.9 M
2019-2.4 M

About Lantern Pharma Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Lantern Pharma income statement, its balance sheet, and the statement of cash flows. Lantern Pharma investors use historical funamental indicators, such as Lantern Pharma's Net Income Applicable To Common Shares, to determine how well the company is positioned to perform in the future. Although Lantern Pharma investors may use each financial statement separately, they are all related. The changes in Lantern Pharma's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Lantern Pharma's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Lantern Pharma Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Lantern Pharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Loss-12.8 M-12.2 M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Lantern Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lantern Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lantern Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lantern Pharma Stock:
Check out the analysis of Lantern Pharma Correlation against competitors.
To learn how to invest in Lantern Stock, please use our How to Invest in Lantern Pharma guide.
You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.

Complementary Tools for Lantern Stock analysis

When running Lantern Pharma's price analysis, check to measure Lantern Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lantern Pharma is operating at the current time. Most of Lantern Pharma's value examination focuses on studying past and present price action to predict the probability of Lantern Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lantern Pharma's price. Additionally, you may evaluate how the addition of Lantern Pharma to your portfolios can decrease your overall portfolio volatility.
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Commodity Directory
Find actively traded commodities issued by global exchanges
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Is Lantern Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lantern Pharma. If investors know Lantern will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lantern Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.47)
Return On Assets
(0.22)
Return On Equity
(0.33)
The market value of Lantern Pharma is measured differently than its book value, which is the value of Lantern that is recorded on the company's balance sheet. Investors also form their own opinion of Lantern Pharma's value that differs from its market value or its book value, called intrinsic value, which is Lantern Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lantern Pharma's market value can be influenced by many factors that don't directly affect Lantern Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lantern Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lantern Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lantern Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.